

Cynata Therapeutics Files New Patent Application for Cymerus™ Stem Cell Technology in Oncology

- Application filed with IP Australia would expand patent estate to immunotherapy
- Creates new opportunities in the growing field of immunotherapy and reinforces a position in oncology

Melbourne, Australia; 20 June 2017: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced today that the Company has filed a new patent application with IP Australia for oncology-related therapeutic uses of its proprietary Cymerus™ mesenchymal stem cell (MSC) technology.

The patent would cover the application of Cymerus in immunotherapy treatments, including chimeric antigen receptor T cell (CAR-T) and checkpoint inhibitor-based therapies. Cynata recently announced the filing of another patent application with IP Australia covering uses of Cymerus in oncology.

“We are thrilled to announce the filing of this patent application, which would strengthen our intellectual property portfolio in the oncology field and expand commercial opportunities for Cymerus in immunotherapy,” said Dr Ross Macdonald, Cynata’s Managing Director and Chief Executive Officer. “Immunotherapy is one of the most exciting areas in oncology and our new intellectual property ensures Cynata is well-positioned to capitalise on future growth in the field.”

Ends

CONTACTS: Dr Ross Macdonald, CEO, 0412 119343, ross.macdonald@cynata.com
Andrew Ramadge, Australia Media Contact, 0475 797 471, andrew.ramadge@mcpartners.com.au
Laura Bagby, U.S. Media Contact, 312-448-8098, lbagby@6degreespr.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company developing therapies based on its proprietary Cymerus™ stem cell technology platform. Cymerus overcomes critical issues in the production of therapeutic mesenchymal stem cells (MSCs) by enabling the economical manufacture of commercial-scale MSCs, independent of multi-donor limitations. Cymerus’ novel approach utilises induced pluripotent stem cells (iPSCs) derived from a single blood donation to generate mesenchymoangioblasts (MCAs), a precursor that is used to manufacture an unlimited number of therapeutic MSCs. Cynata’s unique “off-the-shelf” Cymerus platform has the potential to create a new standard in the development and manufacture of stem cell therapeutics.